Breast cancer subtypes were identified by microarrays and immunohistochemistry and identified as luminal A, luminal B, nonluminal HER2-neu, and triple-negative tumors.22,23 Of those, luminal A tumors were associated with the most favorable clinical outcome. This evidence concerns the gene ERBB2 and breast carcinoma.